กลไกการเกิดโลหิตจางและบทบาทของ Erythropoietin ในการรักษา Myeloma
Keywords:
-Abstract
-
Downloads
References
Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997,336:1657-64.
Tucci M, Grinello D, Cafforio P, Silvestris F, Dammacco F. Anemia in multiple myeloma: role of deregurated plasma cell apoptosis. Leuk Lymphoma 2002;43:1527-33.
Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994,76:959-62.
Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992;13:151-3.
Ashkenazi A, Dixit V. Death receptors: Sigmaling and modulation.Science 1998;281:1305-8.
Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clinic North America 1992;6:273-84.
Zhang XG, Bataille R, Jourdan M, et al. Granulocytemacrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990;76:2599-605.
Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988,332:83-5.
Kawano M, Yamamoto I, Iwato K, et al. Interleukin-1beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989;73:1646-9
Taylor CW, Grogan TM, Salmon SE. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 1990;75:1114-8.
Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med
;322:1689-92.
Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992;82:648-53.
Ludwig H, Rai K, Blade J, et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recom-mendations. Hematol J 2002;3:121-30.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
Krantz SB. Erythropoietin. Blood 1991;77:419-34.
Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-63.
Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by Y interferon can be corrected by recombinant human erythropoietin. Blood 1991;78:2564-7.
Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9.
Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. Arch Intern Med 1995;155:2069-74.
Dammacco F, Castoldi G, Rodjer S. Eficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-9.
Katz O, Barzilay E, Herman A, et al. Erythropoietin reduces tumor load in a MOPC-315 myeloma mouse model. Blood 2002;100:382b.
Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-6.
Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence -based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
